USPTO serial 77863052
SINUPHANT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SNAPP, TINA LOUISE
- Law office
- DIVISIONAL UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SINUPHANT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
92318 Neumarkt, DE
92318 Neumarkt, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kenneth F. Florek
Kenneth F. Florek Florek & Endres PLLC1156 Avenue of the AmericasSuite 600New York, NY 10036Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the treatment, cure, mitigation or prevention of gingivitis, halitosis, stomatitis, periodontitis, inflammation of the oral cavity and pharyngeal cavity, hypersensitivity of teeth, angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhoea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting, allergy, gynaecological disorders affecting menstruation, sterility, menstrual syndromes, dysmenorrhoea, infertility, genital tract infections, pelvic inflammatory diseases, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities of the head, the extremities, chest, abdomen and organs, neoplasia, breast neoplasm, breast cancer, mamma carcinoma, mastopathy, mastodynia, premenstrual syndrome, climateric complaints, breast pain, blood conditions and disorders, blood circulation disorders, high blood pressure, hypertension, pulmonary diseases, heart rhythm disorders, heart failure, urological diseases, sexually transmitted diseases and inflammatory pelvic diseases, menopausal complaints due to therapeutically induced menopause, tamoxifen induced hot flushes of breast cancer survivors, climactic sleep disturbances, depressive moods, protection of the skeletal system, osteoporosis, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, psycho vegetative disorders, depressive syndrome, anxiety, nervous unrest, peripheral nervous system infections, peripheral nervous system movement disorders, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, diseases and disorders of the kidney, urological disorders, chronic infections of the bladder, cystitis, pyelonephritis, glomerulonephritis, interstitial nephritis, neprholithiasis, cancer, urolith prophylaxis, dizziness, migraine, depression, inflammations of the upper and lower respiratory organs, sinuses, bronchitis, tonsillitis, arthritis, osteoarthritis, fever, cough, cold, Alzheimer's disease, infection of respiratory tract, infection of urinary tract, urinary obstruction, chronic venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of liver, periodontal diseases and dental caries; pharmaceutical preparations for use as an antidepressant, diuretic, hypnotic, sedative, analeptic, and tranquilizer; haemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparations, non-narcotic analgesics, throat lozenges; medicinal preparations in tablet form, namely, menstruation circulation regulating tablets; pharmaceutical preparations, namely, for hormone regulation and hormone replacement; pharmaceutical preparations for sensory organs, namely, for use in ophthalmology, otolaryngology and dermatology; pharmaceutical preparations for regulation and strengthening of the immune system; pharmaceutical preparations for treating of and providing temporary relief for occasional minor irritation, pain, sore mouth, sore gums, sore throat, pain associated with canker sores, pain due to minor irritation or injury of the mouth and gums, pain due to minor dental procedures, pain due to minor irritations caused by dentures or orthodontic appliances, sore gums due to teething in infants and children four months of age and older; pharmaceutical products, namely, medicated dental, gum and mouth washes, medicated dental, gum and mouth rinse, medicated toothpastes, medicated oral-care gels, medicated dental gels, medicated lozenges, cough lozenges, medicated chewing gum, medicated gels and fluids in the nature of dental bleaching gels, gum balms, medicated dental floss, medicated dental tapes, medicated dental ribbons, medicated teeth whitener gels, medicated toothpicks, fluoride chewing gum and chewable tablets for disclosing dental plaque and tartar; pharmaceutical preparations for dental purposes, namely, plaque disclosing reagents, periodontal diagnostic reagents for medical purposes for detecting derivatives from periodontal bacteria, caries, diagnostic reagents for detecting derivatives from caries-causing bacteria and medicines for the prevention and treatment of periodontal diseases, dental caries, canker sores, cold sores, mucositis and oral and tongue cancers; medicated mouth sprays and desensitizers; plant extracts for veterinary and pharmaceutical purposes; sanitary preparations for medical use; sanitary preparations for hygiene, namely, antiseptics, oral antiseptics, disinfectants for hygiene purposes; sanitary preparations for the treatment, cleaning and protection of the skin; dietetic foods adapted for medical use in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; food for medically restricted diets, food for diabetics, food supplements containing plant extracts, food supplements derived from plants or plant extracts, all aforesaid goods in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; vitamin and mineral supplements; food supplements, namely, herbal teas for medicinal purposes and medicinal teas; nutritional additives for medicinal purposes for use in foods and dietary supplements for human consumption; dietetic food supplements; dietary supplements; food supplements and dietary food supplements; mineral food supplements, food supplements based on amino acids, minerals and/or trace elements; dietary supplements; food supplements and dietary food supplements; plant extracts for pharmaceutical purposes; medical plasters; materials for dressings, namely, gauze and bandages; all purpose disinfectants; material for stopping teeth; dental wax | ACTIVE | — |
| 009 | Downloadable electronic publications in the nature of magazines, journals, newsletters, periodicals, catalogues, brochures, manuals, leaflets, package inserts in the field of medicine and phytopharmacy; downloadable electronic publications in the nature of press releases featuring information on medicine and phytopharmacy; pre-recorded magnetic data carriers featuring medicine and phytopharmacy; small weighing, measuring, signalling, checking and supervision apparatus, namely, pocket calculators, scales, balances, measuring rules, thermometers, computer storage devices, namely, flash drives, flash memory cards, memory cards and computer memory hardware to be used as an advertising medium; spectacles, namely, eyeglasses and goggles; protective helmets, namely, bicycle helmets; personal computers; DVD, CD, magnetic-tape recorders and players | ACTIVE | — |
| 028 | Games and playthings, namely, board games, card games, dice games, memory games, party games, action skill games, dolls and puppets; positionable toy figures; gymnastic and sporting articles, namely, treadmills, stair machines, stationary exercise bikes, trampolines, skipping ropes, soccer balls, tennis balls, racket balls; rubber balls for games; hockey pucks, rackets; paddles for use in paddle ball games; decorations for Christmas trees, except lighting apparatus and confectionery | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bionorica AG
- Other trademarks owned by Bionorica AG
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 028
- Similar marks named SINUPHANT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 9, 2012 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 9, 2012 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 16, 2012 | NOAC | CORRECTED NOA E-MAILED | — |
| Feb 14, 2012 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jan 24, 2012 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jan 24, 2012 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jan 24, 2012 | UNTD | REQUEST TO DIVIDE UNTIMELY, REFUSED, OR WITHDRAWN | — |
| Jan 4, 2012 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Dec 31, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 30, 2011 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 30, 2011 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 6, 2011 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 6, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 8, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 9, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 7, 2011 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 7, 2011 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 7, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 8, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 6, 2010 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 6, 2010 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 6, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 23, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 8, 2010 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 13, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 13, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 9, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 9, 2010 | ALIE | ASSIGNED TO LIE | — |
| Feb 17, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 17, 2010 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 17, 2010 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 17, 2010 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 17, 2010 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 12, 2010 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 12, 2010 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 12, 2010 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 8, 2010 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 8, 2010 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 8, 2010 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 5, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 5, 2009 | NWAP | NEW APPLICATION ENTERED | — |